Community Pharmacist Utilization of Legislation That Allows Impact on the Opioid Crisis in the State of Minnesota: A Mixed-Methods Approach.
naloxone
opioid
protocol
social and administrative sciences
syringe
Journal
Journal of pharmacy practice
ISSN: 1531-1937
Titre abrégé: J Pharm Pract
Pays: United States
ID NLM: 8900945
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
16
4
2019
medline:
24
4
2021
entrez:
16
4
2019
Statut:
ppublish
Résumé
As opioid overdose deaths climb, legislation supporting pharmacists in developing their role to address the crisis has expanded. Although Minnesota pharmacists are encouraged to utilize opiate antagonist, syringe access and authorized collector legislation, the use patterns of these tools are unknown. A mixed-methods approach was used to survey 8405 Minnesota-licensed pharmacists on their practices related to the opioid crisis. An analysis of community pharmacist utilization of opioid-related legislation was conducted. The majority (88.64%) of respondents indicated that they had not dispensed naloxone in the past month using a protocol; 59.69% reported that they had not dispensed naloxone by any method in the past month. Over sixty percent (60.61%) of respondents agreed they are comfortable with dispensing syringes and would dispense noninsulin syringes in their pharmacy under the statewide Syringe Access Initiative; 25.86% reported that they are not comfortable dispensing syringes. The majority (78.64%) of respondents reported that they do not participate in collecting unwanted pharmaceuticals. While pharmacists have the potential to play a key role in efforts focused on addressing the opioid crisis through harm reduction strategies, this role and the use of supporting legislation is currently underutilized in the state of Minnesota.
Sections du résumé
BACKGROUND
BACKGROUND
As opioid overdose deaths climb, legislation supporting pharmacists in developing their role to address the crisis has expanded. Although Minnesota pharmacists are encouraged to utilize opiate antagonist, syringe access and authorized collector legislation, the use patterns of these tools are unknown.
METHODS
METHODS
A mixed-methods approach was used to survey 8405 Minnesota-licensed pharmacists on their practices related to the opioid crisis. An analysis of community pharmacist utilization of opioid-related legislation was conducted.
RESULTS
RESULTS
The majority (88.64%) of respondents indicated that they had not dispensed naloxone in the past month using a protocol; 59.69% reported that they had not dispensed naloxone by any method in the past month. Over sixty percent (60.61%) of respondents agreed they are comfortable with dispensing syringes and would dispense noninsulin syringes in their pharmacy under the statewide Syringe Access Initiative; 25.86% reported that they are not comfortable dispensing syringes. The majority (78.64%) of respondents reported that they do not participate in collecting unwanted pharmaceuticals.
CONCLUSION
CONCLUSIONS
While pharmacists have the potential to play a key role in efforts focused on addressing the opioid crisis through harm reduction strategies, this role and the use of supporting legislation is currently underutilized in the state of Minnesota.
Identifiants
pubmed: 30983492
doi: 10.1177/0897190019841747
pmc: PMC6848773
mid: NIHMS1057425
doi:
Substances chimiques
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-808Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000114
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Références
Public Health Rep. 1998 Jun;113 Suppl 1:75-80
pubmed: 9722812
JAMA. 2015 Jul 7;314(1):23-4
pubmed: 26000661
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S28-S33
pubmed: 28139459
Ann Pharmacother. 2014 May;48(5):601-6
pubmed: 24523396
Br J Anaesth. 2008 Jun;100(6):747-58
pubmed: 18456641
Res Social Adm Pharm. 2019 Aug;15(8):992-999
pubmed: 30442574
J Am Board Fam Med. 2006 Nov-Dec;19(6):542-7
pubmed: 17090787
Eur J Pharmacol. 2002 Jun 7;445(1-2):61-7
pubmed: 12065195
Integr Pharm Res Pract. 2016 Aug 25;5:65-73
pubmed: 29354541
Addict Sci Clin Pract. 2017 Jan 7;12(1):4
pubmed: 28061909
Ann Intern Med. 2016 Aug 16;165(4):245-52
pubmed: 27366987
Subst Abuse Rehabil. 2017 Jul 31;8:53-55
pubmed: 28814912
Subst Abus. 2018;39(3):331-341
pubmed: 29043922
J Am Pharm Assoc (2003). 2018 Jan - Feb;58(1):21-29
pubmed: 29074146
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S12-S18.e4
pubmed: 28163027
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S141-S147
pubmed: 28209338
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
J Addict Dis. 2006;25(3):89-96
pubmed: 16956873
Pharmacy (Basel). 2018 Nov 29;6(4):
pubmed: 30501035
Res Social Adm Pharm. 2018 Oct;14(10):968-978
pubmed: 29239777
Subst Abus. 2018;39(2):193-198
pubmed: 29432081
Res Social Adm Pharm. 2019 Aug;15(8):910-916
pubmed: 29325708
Am J Pathol. 2004 Jun;164(6):1875-82
pubmed: 15161623
J Int Med Res. 2018 Mar;46(3):927-939
pubmed: 29322845
Am J Emerg Med. 1994 Nov;12(6):650-60
pubmed: 7945608
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S19-S27.e4
pubmed: 28214219
Curr Pharm Teach Learn. 2018 Jan - Feb;10(1):72-77
pubmed: 29248078
Waste Manag Res. 2012 Jun;30(6):625-30
pubmed: 22081380
Int J Drug Policy. 2010 May;21(3):186-93
pubmed: 19268564
Res Social Adm Pharm. 2016 Nov - Dec;12(6):937-948
pubmed: 26806859
J Urban Health. 2005 Jun;82(2):303-11
pubmed: 15872192
Eur J Anaesthesiol. 2003 Feb;20(2):127-33
pubmed: 12622497
J Law Med Ethics. 2013 Mar;41 Suppl 1:33-6
pubmed: 23590737